Last reviewed 2026-05-23 · How we verify

Boanmycin

Tianjin Medical University Cancer Institute and Hospital · Phase 2 active Small molecule ✓ Verified May 2026

Boanmycin is a Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital. It is currently in Phase 2 development. Also known as: Boanmycin Hydrochloride for Injection.

Boanmycin is a DNA disrupting agent, classified as a disrupting agent. It is being studied in combination with Docetaxel for the treatment of Squamous Cell Lung Cancer.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Boanmycin
Also known as	Boanmycin Hydrochloride for Injection
Sponsor	Tianjin Medical University Cancer Institute and Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Boanmycin CI brief — competitive landscape report
Boanmycin updates RSS · CI watch RSS
Tianjin Medical University Cancer Institute and Hospital portfolio CI

Frequently asked questions about Boanmycin

What is Boanmycin?

Boanmycin is a Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital.

Who makes Boanmycin?

Boanmycin is developed by Tianjin Medical University Cancer Institute and Hospital (see full Tianjin Medical University Cancer Institute and Hospital pipeline at /company/tianjin-medical-university-cancer-institute-and-hospital).

Is Boanmycin also known as anything else?

Boanmycin is also known as Boanmycin Hydrochloride for Injection.

What development phase is Boanmycin in?

Boanmycin is in Phase 2.

Manufacturer: Tianjin Medical University Cancer Institute and Hospital — full pipeline
Therapeutic area: All drugs in Other
Also known as: Boanmycin Hydrochloride for Injection

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing